However, the medical agents currently available for controlling hypercortisolism and targeting corticotroph pituitary tumours, adrenal glands, or glucocorticoid receptors are effective in subsets of patients with CS [3, 4]. The gene discussed is NR3C1; the disease is pituitary tumor.